The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.
Transcript
What are the barriers to preventing the transmission of HIV/AIDS?
I think as we learn more and do more studies on the use of pre-exposure prophylaxis, that the data’s going to be overwhelming. I mean, we’re really only two, three years into these studies and I think it does take some time. Also, the cost needs to decrease. But I think as we do more studies, show more efficacy, and get better acceptance in the countries that have been reticent to accept it, I think we’ll make some headway. So that’s number one.
The second means of prevention is treating the HIV-infected person. So, how are we doing with that? Right now, probably less than 45 percent of the world’s HIV population is under treatment and virally suppressed. So that’s good news, that those individuals are non-infectious or less infectious to their sexual partners, but that means 55 percent of the world’s population is untreated. And that is probably one of the biggest barriers.
It’s getting people to, one, be screened and be tested and to know they’re infected, two, to get them into care, and three, to get them put onto anti-retroviral drugs once in care, and then fourth and lastly, make sure they’re suppressed. If they’re virally suppressed, they’re non-infectious. There’s really been almost no transmissions of individuals who have a completely suppressed viral load of HIV. So I would say the two biggest barriers right now in prevention is not enough people on treatment that need to be on treatment and virally suppressed, and two, the high-risk individuals not getting pre-exposure prophylaxis, which can block HIV acquisition.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
Sexual, Gender Minority Communities Misperceive Risk of HIV
July 22nd 2025A new study shows low rates of pre-exposure prophylaxis (PrEP) prescribing to sexual and gender minority individuals living in North Carolina, indicating barriers like stigma and a misperception of risk as reasons for not using PrEP.
Read More